Log in to your account:
Canaccord Genuity Sees Bristol-Myers Acquiring Control of bb2121 from bluebird bio (BLUE)
January 24, 2019 10:32 AM
Canaccord Genuity analyst John Newman expects Bristol-Myers (NYSE: BMY) to acquire 100% control of bb2121 from bluebird bio (NASDAQ: BLUE) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Mergers and Acquisitions
BMO Capital Reiterates Outperform on Bristol-Myers Squibb (BMY)
January 25, 2019 8:45 AM